COVID-19 Vaccine: Pfizer Halves Vaccines of 2020
COVID-19 Vaccine: Pfizer Halves Vaccines of 2020. Pfizer aims to halve its COVID-19 vaccine production this year due to multiple challenges in the supply chain–Wall Street Journal
Reuters, December 3-The Wall Street Journal reported on Thursday that the challenges facing Pfizer’s COVID-19 vaccine supply chain had an impact on the company’s decision to slash its 2020 production target.
Pfizer said in recent weeks that it expects to produce 50 million doses of the COVID-19 vaccine this year. This figure is lower than the previous 100 million dose target. Since Pfizer vaccine requires two doses, it means that 50 million doses are enough for 25 million people.
A Pfizer spokesperson told the Wall Street Journal that “it takes longer than expected to increase the output of the raw material supply chain.” According to the report, she also pointed out that Pfizer’s clinical trial results were released later than expected, which is one reason why the company lowered its production forecast for this year. One.
The Wall Street Journal reported that an unnamed person directly involved in the development of Pfizer’s vaccine stated that “the earlier batches of raw materials failed to meet the standards”, which caused production delays.
Pfizer applied to US regulators for emergency use authorization of its COVID-19 vaccine in November. US officials said they expect the vaccine to receive regulatory approval this month. The US government expects that the first batch of vaccines will include 6.4 million doses, and more will be supplied in the future.
British regulators have authorized the use of Pfizer vaccines in the UK.
Pfizer has not yet responded to requests for comment on the report